FDA Approves First Fully Oral Regimen of INQOVI + Venetoclax for Acute Myeloid Leukemia
The FDA has approved the combination of INQOVI tablets and venetoclax for adults with newly diagnosed AML who are unable to undergo intensive chemotherapy. In the study, complete remission was achieved in 41.6% of patients, making this approach the first approved fully oral regimen for this patient population.
Not a pill, but a game-changer: how the oral INQOVI + venetoclax regimen reshapes the rules of the AML market
[The Gist]: What's really happening
On May 13, 2026, the FDA approved the combination of INQOVI (decitabine + cedazuridine) with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. At first glance, it's just another regulatory decision. But this is a case where form matters more than substance. The main event is not the molecule itself (both components have been known for a long time), but the change in delivery method. The first fully oral regimen for this population shifts therapy from the "clinic visit" category to the "morning pill" category. The market instantly picks up on this: the market capitalization of the oral leukemia therapy segment, according to Fortune Business Insights, is projected to grow from $25.67 billion in 2026 to $46.75 billion by 2034.
Timeline and Context
The path to approval took about four years from the launch of the Phase II ASCERTAIN-V trial. The key date was the publication of results in The Lancet Haematology in summer 2025: 42 out of 101 patients achieved complete remission (41.6%), the median duration of response was not reached, and 75.3% of patients maintained remission at 12 months.
But the context is more important for understanding. Before May 13, 2026, the standard for elderly/unfit AML was a combination of an injectable hypomethylating agent (azacitidine or decitabine) with venetoclax—a regimen requiring 7 clinic visits per month just for infusions. This is a logistical nightmare for a patient aged 75+, often living an hour away from the cancer center. Taiho Oncology did something simple but brilliant: replaced the IV with a pill by adding cedazuridine to decitabine—a cytidine deaminase inhibitor that prevents the gut from breaking down the drug before it enters the bloodstream.
Who Wins and Who Loses
Winners:
- Taiho Oncology and Otsuka Group. INQOVI was already approved for MDS and CMML, but the AML market is a different scale. In 2026, 22,720 new AML cases are expected in the US, more than half of which are candidates for the new regimen. At a course price comparable to the injectable counterpart ($15,000–18,000 per month), this translates to a potential annual revenue of over $1.2 billion in the US alone.
- Patients aged 75+. The need to travel to the clinic twice a week disappears. For a family living in a rural area, this saves dozens of hours per month and thousands of dollars in transportation and care.
- Outpatient oncology services. The oral regimen eases the burden on infusion centers. In a system where the cost of one bed-day in an oncology hospital can reach $5,000, this is a direct saving for insurance companies.
Losers:
- Manufacturers of injectable hypomethylating agents, especially azacitidine generics. Their competitive advantage—price—is eroded by the convenience of oral administration. Insurance companies will increasingly favor an oral-first strategy.
- Clinics whose economics depend on infusion procedures. Fewer infusions mean lower revenue for procedure rooms.
- Patients with TP53 mutations (16.8% in the study cohort)—their response is worse than the population average, although the regimen is formally approved without restrictions based on cytogenetic risk.
What the Media Isn't Saying
Insight 1: The race for oral platforms is just beginning, and Taiho is not the only player.
What is being presented as a "breakthrough" is actually a natural step in the evolution of the hypomethylating agent class. At least three drugs in the pipelines of AbbVie and Bristol-Myers Squibb are currently undergoing a similar oral pathway. Cedazuridine as the "key" to oral bioavailability is a technology platform that Taiho can license or use to create combinations with other drugs. In other words, INQOVI is not a product but a proof of concept for an entire family of oral onco-hematology regimens.
Insight 2: The FDA conducted an accelerated approval (Project Orbis) in conjunction with Health Canada, but the EMA decision will come later and may be stricter.
Project Orbis is an FDA initiative for parallel review of oncology drugs with international regulators. However, the European EMA traditionally requires more convincing data on overall survival (not just CR and DoCR). Currently, the median OS is 15.5 months versus 14.7 months for azacitidine + venetoclax in VIALE-A. The difference is not statistically significant. If no new data emerges by fall 2026, the EMA may either delay registration or impose stricter criteria for use.
Forecast: Next 30 Days and 90 Days
30 days (by mid-June 2026):
Taiho Oncology is expected to announce the commercial price and access conditions under the patient assistance program. Active negotiations with insurance companies to include the regimen in first-line formularies will begin. Concurrently, AbbVie (the manufacturer of venetoclax) will update dosing recommendations in light of the new approval—and this will de facto make INQOVI + venetoclax the de facto standard for unfit AML even before the updated NCCN Guidelines are published.
90 days (by mid-August 2026):
A post-hoc analysis of ASCERTAIN-V on quality of life and pharmacoeconomics is likely to be published—these data will be decisive for European regulators. The first major real-world evidence (RWE) study based on Flatiron Health or SEER-Medicare data is expected, showing how the oral regimen works outside clinical trials—in a population with more pronounced comorbidity. If the results are confirmed, by the end of 2026 the oral regimen could capture over 40% of the first-line unfit AML market in the US.
Bottom line: The approval of INQOVI + venetoclax is not so much a medical sensation as a signal to the market. The era of infusion hematology is gradually giving way to oral therapy. Whoever builds a convenient and safe oral ecosystem first will win the race for the elderly patient who no longer wants to be a "patient on a needle."
— Editorial Team
